OpenAI CEO Sam Altman said that GPT-5, the company’s next probable large AI model, likely won’t come this year.
Jefferies says buy this pharmaceutical play, sees more than 100% upside from here
This pharmaceutical company’s recent drug developments could spell more gains ahead, according to Jefferies.